BioWorld Asia

May 5, 2010

Oxford Immunotec Raises $26M to Boost T-Cell Tests Worldwide

LONDON - Oxford Immunotec Ltd. raised $26 million in a fourth-round funding, which it said will enable it to increase sales of its T-cell diagnostic for tuberculosis and take the company through to profitability. (BioWorld International) Read More

Asian Pacific Biotechs Branch Out from Health to White Tech

Study Pinpoints Viral RNA Targets for Future Drugs

Huntington's Drug Snagged on Statistics; Another Trial Needed?

BIO in Chicago: BioWorld Waxes Nostalgic, Biotech Perseveres

Affimed Plans to Take Antibodies into Clinic with $26M Series C

Protox's $75M Kissei Deal May Set Stage for Larger Alliances

Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

BioWorld Science

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...